Advancing human pulmonary disease models in preclinical research: opportunities for lung-on-chips..
dc.contributor.author | Artzy-Schnirman, Arbel | |
dc.contributor.author | Lehr, Claus-Michael | |
dc.contributor.author | Sznitman, Josué | |
dc.date.accessioned | 2020-04-23T13:04:17Z | |
dc.date.available | 2020-04-23T13:04:17Z | |
dc.date.issued | 2020-03-11 | |
dc.identifier.citation | Expert Opin Drug Deliv. 2020 Mar 11:1-5. doi: 10.1080/17425247.2020.1738380. | en_US |
dc.identifier.pmid | 32129105 | |
dc.identifier.doi | 10.1080/17425247.2020.1738380 | |
dc.identifier.uri | http://hdl.handle.net/10033/622242 | |
dc.description.abstract | [No abstracr available] | en_US |
dc.language.iso | en | en_US |
dc.publisher | Taylor&Francis | en_US |
dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | Preclinical research | en_US |
dc.subject | lung diseases | en_US |
dc.subject | microfluidics | en_US |
dc.subject | organ-on-chips | en_US |
dc.subject | respiratory therapy | en_US |
dc.title | Advancing human pulmonary disease models in preclinical research: opportunities for lung-on-chips.. | en_US |
dc.type | Editorial | en_US |
dc.type | Other | en_US |
dc.identifier.eissn | 1744-7593 | |
dc.contributor.department | HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany. | en_US |
dc.identifier.journal | Expert opinion on drug delivery | en_US |
dc.source.beginpage | 1 | |
dc.source.endpage | 5 | |
dc.source.journaltitle | Expert opinion on drug delivery | |
dc.source.country | England |